Synthesis of cis-dichloro-(pyridine-2-carboxaldimine)platinum(II) compounds for potential anticancer application

Abstract

In an effort to develop effective long-term and short-term cancer treatment methods, research over the last fifty years has focused itself in a variety of areas including radiation and chemotherapy treatments. One of the first anticancer drugs discovered, cisplatin (cis-PtCl2(NH3)2) has had promising results in reducing the proliferation of cancer cells. Millions of patients diagnosed with a range of different cancers have benefited from the use of cisplatin. Even with the benefits, there are a number of major problems involving this drug that have limited its clinical applications, such as acquired drug resistance and cytotoxicity. Consequently, in the last thirty years, analogues of cisplatin complexes have been an important area of research in order to combat these issues. Even though the design is similar, more effective anticancer drugs have been in question. In this study, two novel platinum analogues of cisplatin were prepared. Compound 2a was fabricated by beginning with the synthesis of the bulky and lipophilic ligands which was then added to [PtCl2(cis-cyclooctene)]2 to create the desired platinum compound. Compound 2b, using the same procedure, was successfully synthesized, but with alterations on the ligand (1b). All compounds produced moderate yields and were characterised using 1H NMR, 13C{1H} NMR and FTIR spectroscopy. Detailed analysis of these spectrums concluded that these compounds were successfully synthesized. For this reason, further application of these compounds is promising and with biological testing there may be hope for new and more efficient novel anticancer compounds.